The effect of nephrectomy on Klotho, FGF-23 and bone metabolism

被引:9
|
作者
Kakareko, Katarzyna [1 ]
Rydzewska-Rosolowska, Alicja [1 ]
Brzosko, Szymon [1 ]
Gozdzikiewicz-Lapinska, Joanna [2 ]
Koc-Zorawska, Ewa [2 ]
Samocik, Pawel [3 ]
Kozlowski, Robert [3 ]
Mysliwiec, Michal [1 ]
Naumnik, Beata [1 ]
Hryszko, Tomasz [1 ]
机构
[1] Med Univ Bialystok, Dept Nephrol & Transplantat 1, Dialysis Unit, Ul Zurawia 14, PL-15540 Bialystok, Poland
[2] Med Univ Bialystok, Dept Hypertens & Nephrol 1, Dialysis Unit, Bialystok, Poland
[3] J Sniadecki Prov Hosp, Dept Oncol & Gen Urol, Bialystok, Poland
关键词
Acute GFR decline; Nephrectomy; Klotho; FGF-23; Bone metabolism; GROWTH-FACTOR; 23; ACUTE KIDNEY INJURY; MINERAL METABOLISM; CARDIAC-SURGERY; SERUM-LEVELS; PHOSPHATE; DISEASE; FGF23; CKD; FACTOR-23;
D O I
10.1007/s11255-017-1519-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Increased concentration of fibroblast growth factor 23 (FGF-23) and decreased levels of soluble Klotho (sKL) are linked to negative clinical outcomes among patients with chronic kidney disease and acute kidney injury. Therefore, it is reasonable to hypothesize that GFR reduction caused by nephrectomy might alter mineral metabolism and induces adverse consequences. Whether nephrectomy due to urological indications causes derangements in FGF-23 and sKL has not been studied. The aim of the study was to evaluate the effect of acute GFR decline due to unilateral nephrectomy on bone metabolism, FGF-23 and sKL levels. Methods This is a prospective, single-centre observational study of patients undergoing nephrectomy due to urological indications. Levels of C-terminal FGF-23 (c-FGF-23), sKL and bone turnover markers [beta-crosslaps (CTX), bone-specific alkaline phosphatase (bALP) and tartrate-resistant acid phosphatase 5b (TRAP 5b)] were measured before and after surgery (5 +/- 2 days). Results Twenty-nine patients were studied (14 females, age 63.0 +/- 11.6, eGFR 87.3 +/- 19.2 ml/min/1.73 m(2)). After surgery, eGFR significantly declined (p < 0.0001). Nephrectomy significantly decreased sKL level [709.8 (599.9-831.2) vs. 583.0 (411.7-752.6) pg/ml, p < 0.001] and did not change c-FGF-23 concentration [70.5 (49.8-103.3) vs. 77.1 (60.5-109.1) RU/ml, p = 0.9]. Simultaneously, alterations in bone turnover markers were observed. Serum concentration of CTX increased [0.49 (0.4-0.64) vs. 0.59 (0.46-0.85) ng/ml, p = 0.001], while bALP and TRAP 5b decreased [23.6 (18.8-31.4) vs. 17.9 (15.0-22.0) U/l, p < 0.0001 and 3.3 (3.0-3.7) vs. 2.8 (2.3-3.2) U/l, p < 0.001, respectively]. Conclusions Nephrectomy among patients with preserved renal function before surgery does not increase c-FGF-23 but reduces sKL. Moreover, nephrectomy results in derangements in bone turnover markers in short-term follow-up. These changes may participate in pathogenesis of bone disease after nephrectomy.
引用
收藏
页码:681 / 688
页数:8
相关论文
共 50 条
  • [31] Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism
    Hryszko, Tomasz
    Brzosko, Szymon
    Rydzewska-Rosolowska, Alicja
    Koc-Zorawska, Ewa
    Mysliwiec, Michal
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (05) : 1479 - 1486
  • [32] PTH, FGF-23 and early CKD
    Rodriguez, Mariano
    Felsenfeld, Arnold J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (11)
  • [33] The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation
    Gupta, Meera
    Orozco, Gabriel
    Rao, Madhumati
    Gedaly, Roberto
    Malluche, Hartmut H.
    Neyra, Javier A.
    FRONTIERS IN MEDICINE, 2022, 9
  • [34] The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents
    Kutluturk, Yesim
    Akinci, Aysehan
    Ozerol, Ibrahim Halil
    Yologlu, Saim
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2019, 32 (07) : 707 - 714
  • [35] FGF-23: just a phosphate metabolism regulator or something else?
    Carmen Sanchez-Gonzalez, Maria
    Salanova, Laura
    Ruano, Pablo
    REUMATOLOGIA CLINICA, 2011, 7 : S5 - S7
  • [36] FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment
    Seiler, Sarah
    Reichart, Birgit
    Roth, Daniel
    Seibert, Eric
    Fliser, Danilo
    Heine, Gunnar H.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (12) : 3983 - 3989
  • [37] Assessment of Clinical Utility of Assaying FGF-23, Klotho Protein, Osteocalcin, NTX, and Sclerostin in Patients with Primary Hyperparathyroidism
    Sykala, Monika
    Szumowski, Piotr
    Mojsak, Malgorzata
    Abdelrazek, Saeid
    Zukowski, Lukasz
    Lipinska, Danuta
    Juchnicka, Ilona
    Kozlowska, Gabryela
    Szelachowska, Malgorzata
    Kretowski, Adam
    Mysliwiec, Janusz
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [38] Clearance of FGF-23 during continuous renal replacement therapy
    Sharma, Shilpa
    Christov, Marta
    Ix, Joachim H.
    Waikar, Sushrut S.
    HEMODIALYSIS INTERNATIONAL, 2019, 23 (03) : 366 - 368
  • [39] A short story of Klotho and FGF23: a deuce of dark side or the savior?
    Ersoy, F. Fevzi
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (03) : 577 - 581
  • [40] FGF-23 Levels in Patients with AKI and Risk of Adverse Outcomes
    Leaf, David E.
    Wolf, Myles
    Waikar, Sushrut S.
    Chase, Herbert
    Christov, Marta
    Cremers, Serge
    Stern, Leonard
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (08): : 1217 - 1223